Oscar Fernandez-Capetillo Group
The Fernández-Capetillo laboratory focuses on the use of cell-based phenotypic screens for the development of new medicines. Neglected until rather recently, due to a focus on target-oriented drug development, phenotypic screens have yielded some of the most important medical advances to our societies. With the help of automatized microscopes, the laboratory designs phenotypic screens that aim to mimic a disease condition.
The research mostly focuses on diseases that are largely neglected by the industry, or in the repositioning of current medically approved drugs for their use in other diseases.
Our recently started laboratory at Karolinska Institutet focuses on the implementation of cell-based phenotypic screens oriented to the discovery and development of novel molecules to improve the efficiency of various diseases. At present, our interests are spread among a variety of topics, such as the discovery of new medicines for amyotrophic lateral sclerosis (ALS), the search for chemical modulators of the immune response, or the discovery of molecules that can regulate the levels of RNA and protein production in cells.
|Jordi Carreras Puigvert||Assistant professor, Project manager|
|Alba Corman||PhD student|
|Maria Häggblad||Research engineer|
|Xuexin Li||Graduate Student|
|Louise Lidemalm||Laboratory technician|
|Per Moberg||Research coordinator|
The lab is looking for talented and highly motivated postdoctoral fellows. We seek candidates that have a strong expertise in molecular and cell biology. The person should have deep knowledge in cancer biology or ALS research. Preference will be given to applicants with skills in high-content imaging, automated image processing and gene knockout (CRISPR/Cas9) strategies. The successful candidate should have a strong publication record. Complete fluency in both written and spoken English is a request. The candidate´s personal skills will be highly valued.
Please contact Per Moberg at email@example.com directly if you are interested. Postdocs are asked to send a motivation letter and their CV.
- Kirsten Tschapalda, now Senior Scientist at AstraZeneca, UK
- Bomi Jung,now Senior Scientist at AstraZeneca, Mölndal, Sweden
A Chemical Screen Identifies Compounds Limiting the Toxicity of C9ORF72 Dipeptide Repeats.
Corman A, Jung B, Häggblad M, Bräutigam L, Lafarga V, Lidemalm L, et al
Cell Chem Biol 2019 Feb;26(2):235-243.e5
A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors.
Ruiz S, Mayor-Ruiz C, Lafarga V, Murga M, Vega-Sendino M, Ortega S, et al
Mol. Cell 2016 04;62(2):307-313
USP7 is a SUMO deubiquitinase essential for DNA replication.
Lecona E, Rodriguez-Acebes S, Specks J, Lopez-Contreras AJ, Ruppen I, Murga M, et al
Nat. Struct. Mol. Biol. 2016 Apr;23(4):270-7
NSMCE2 suppresses cancer and aging in mice independently of its SUMO ligase activity.
Jacome A, Gutierrez-Martinez P, Schiavoni F, Tenaglia E, Martinez P, Rodríguez-Acebes S, et al
EMBO J. 2015 Nov;34(21):2604-19
Limiting replication stress during somatic cell reprogramming reduces genomic instability in induced pluripotent stem cells.
Ruiz S, Lopez-Contreras AJ, Gabut M, Marion RM, Gutierrez-Martinez P, Bua S, et al
Nat Commun 2015 Aug;6():8036
Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice.
Lopez-Contreras AJ, Specks J, Barlow JH, Ambrogio C, Desler C, Vikingsson S, et al
Genes Dev. 2015 Apr;29(7):690-5
The maternal side of Fanconi Anemia.
Ruiz S, Fernandez-Capetillo O
Mol. Cell 2014 Sep;55(6):803-804